CHU de Lille at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
CHU de Lille brings 10 presentations to ASH 2026 in New Orleans. Its program centres on myeloma, acute myeloid leukemia and hypereosinophilic syndrome. It includes comparisons of elranatamab with standard regimens and measurable residual disease testing.
| Organization | ASH 2026 Attendance |
|---|---|
CHU de Lille Lille, France | |
Lille University Hospital, a large public teaching hospital in northern France. | Symposium Fri Dec 11 7:00am–10:00am Anti-BCMA Bispecific Antibodies in Multiple Myeloma: From Biology to Real-World Implementation Bispecific antibodies targeting B-cell maturation antigen in myeloma, from mechanism and resistance to trial data, outpatient dosing, and infection prevention. Oral Sat Dec 12 4:00pm–5:30pm Poster Sat Dec 12 5:30pm–7:30pm Poster Sat Dec 12 5:30pm–7:30pm Poster Sat Dec 12 5:30pm–7:30pm Oral Sun Dec 13 4:30pm–6:00pm Poster Sun Dec 13 6:00pm–8:00pm Oral Mon Dec 14 4:30pm–6:00pm Poster Mon Dec 14 6:00pm–8:00pm Poster Mon Dec 14 6:00pm–8:00pm |
Find decision makers at CHU de Lille
Tell us what you sell and we’ll find the people at CHU de Lille most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction